{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:24:14Z","timestamp":1790807054327,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,3,21]],"date-time":"2014-03-21T00:00:00Z","timestamp":1395360000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s10928-014-9355-3","type":"journal-article","created":{"date-parts":[[2014,3,20]],"date-time":"2014-03-20T09:06:26Z","timestamp":1395306386000},"page":"173-185","source":"Crossref","is-referenced-by-count":19,"title":["Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate"],"prefix":"10.1007","volume":"41","author":[{"name":"The CRESim & Epi-CRESim Project Groups","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayode","family":"Ogungbenro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Aarons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,21]]},"reference":[{"key":"9355_CR1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s002800050405","volume":"37","author":"F Innocenti","year":"1996","unstructured":"Innocenti F, Danesi R, Di Paolo A, Loru B, Favre C, Nardi M, Bocci G, Nardini D, Macchia P, Del Tacca M (1996) Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Cancer Chemother Pharmacol 37:409\u2013414","journal-title":"Cancer Chemother Pharmacol"},{"key":"9355_CR2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00007691-200406000-00016","volume":"26","author":"LJ Derijks","year":"2004","unstructured":"Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, Curvers WL, Van Deventer SJ, Hommes DW, Hooymans PM (2004) Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 26:311\u2013318","journal-title":"Ther Drug Monit"},{"key":"9355_CR3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1046\/j.1442-200X.2001.01475.x","volume":"43","author":"H Mawatari","year":"2001","unstructured":"Mawatari H, Unei K, Nishimura S, Sakura N, Ueda K (2001) Comparative pharmacokinetics of oral 6-mercaptopurine and intravenous 6-mercaptopurine riboside in children. Pediatr Int 43:673\u2013677","journal-title":"Pediatr Int"},{"key":"9355_CR4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrc1800","volume":"6","author":"MH Cheok","year":"2006","unstructured":"Cheok MH, Evans WE (2006) Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 6:117\u2013129","journal-title":"Nat Rev Cancer"},{"key":"9355_CR5","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJM198304283081705","volume":"308","author":"S Zimm","year":"1983","unstructured":"Zimm S, Collins JM, Riccardi R, O\u2019Neill D, Narang PK, Chabner B, Poplack DG (1983) Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 308:1005\u20131009","journal-title":"N Engl J Med"},{"key":"9355_CR6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/08880018609031198","volume":"3","author":"G Lonnerholm","year":"1986","unstructured":"Lonnerholm G, Kreuger A, Lindstrom B, Ludvigsson J, Myrdal U (1986) Plasma and erythrocyte concentrations of mercaptopurine after oral administration in children. Pediatr Hematol Oncol 3:27\u201335","journal-title":"Pediatr Hematol Oncol"},{"key":"9355_CR7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF02220605","volume":"43","author":"L Lennard","year":"1992","unstructured":"Lennard L (1992) The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 43:329\u2013339","journal-title":"Eur J Clin Pharmacol"},{"key":"9355_CR8","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/blood.V92.10.3569","volume":"92","author":"FM Balis","year":"1998","unstructured":"Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF, Ames MM, Waskerwitz MJ, Tubergen DG, Zimm S, Gilchrist GS, Bleyer WA (1998) Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children\u2019s cancer group and pediatric oncology branch study. Blood 92:3569\u20133577","journal-title":"Blood"},{"key":"9355_CR9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2125.2004.02114.x","volume":"58","author":"I Matthews","year":"2004","unstructured":"Matthews I, Kirkpatrick C, Holford N (2004) Quantitative justification for target concentration intervention\u2014parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol 58:8\u201319","journal-title":"Br J Clin Pharmacol"},{"key":"9355_CR10","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/jps.2600661027","volume":"66","author":"L Tterlikkis","year":"1977","unstructured":"Tterlikkis L, Ortega E, Solomon R, Day JL (1977) Pharmacokinetics of mercaptopurine. J Pharm Sci 66:1454\u20131457","journal-title":"J Pharm Sci"},{"key":"9355_CR11","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1365-2125.2008.03281.x","volume":"66","author":"AF Hawwa","year":"2008","unstructured":"Hawwa AF, Collier PS, Millership JS, McCarthy A, Dempsey S, Cairns C, McElnay JC (2008) Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. Br J Clin Pharmacol 66:826\u2013837","journal-title":"Br J Clin Pharmacol"},{"key":"9355_CR12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/sj.leu.2402373","volume":"16","author":"T Dervieux","year":"2002","unstructured":"Dervieux T, Hancock M, Evans W, Pui CH, Relling MV (2002) Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine. Leukemia 16:209\u2013212","journal-title":"Leukemia"},{"key":"9355_CR13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0306-3623(99)00022-1","volume":"33","author":"T Giverhaug","year":"1999","unstructured":"Giverhaug T, Loennechen T, Aarbakke J (1999) The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX). Gen Pharmacol 33:341\u2013346","journal-title":"Gen Pharmacol"},{"key":"9355_CR14","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/clpt.1987.45","volume":"41","author":"FM Balis","year":"1987","unstructured":"Balis FM, Holcenberg JS, Zimm S, Tubergen D, Collins JM, Murphy RF, Gilchrist GS, Hammond D, Poplack DG (1987) The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin Pharmacol Ther 41:384\u2013387","journal-title":"Clin Pharmacol Ther"},{"key":"9355_CR15","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1365-2125.2009.03479.x","volume":"68","author":"K Ogungbenro","year":"2009","unstructured":"Ogungbenro K, Matthews I, Looby M, Kaiser G, Graham G, Aarons L (2009) Population pharmacokinetics and optimal design of paediatric studies for famciclovir. Br J Clin Pharmacol 68:546\u2013560","journal-title":"Br J Clin Pharmacol"},{"key":"9355_CR16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0022-3565(24)37815-2","volume":"287","author":"R Kawai","year":"1998","unstructured":"Kawai R, Mathew D, Tanaka C, Rowland M (1998) Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-upto human. J Pharmacol Exp Ther 287:457\u2013468","journal-title":"J Pharmacol Exp Ther"},{"key":"9355_CR17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/BF02353860","volume":"22","author":"R Kawai","year":"1994","unstructured":"Kawai R, Lemaire M, Steimer JL, Bruelisauer A, Niederberger W, Rowland M (1994) Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J Pharmacokinet Biopharm 22:327\u2013365","journal-title":"J Pharmacokinet Biopharm"},{"key":"9355_CR18","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/clpt.1983.254","volume":"34","author":"S Zimm","year":"1983","unstructured":"Zimm S, Collins JM, O\u2019Neill D, Chabner BA, Poplack DG (1983) Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 34:810\u2013817","journal-title":"Clin Pharmacol Ther"},{"key":"9355_CR19","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","volume":"45","author":"TN Johnson","year":"2006","unstructured":"Johnson TN, Rostami-Hodjegan A, Tucker GT (2006) Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 45:931\u2013956","journal-title":"Clin Pharmacokinet"},{"key":"9355_CR20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0022-3476(78)80601-5","volume":"93","author":"GB Haycock","year":"1978","unstructured":"Haycock GB, Schwartz GJ, Wisotsky DH (1978) Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr 93:62\u201366","journal-title":"J Pediatr"},{"key":"9355_CR21","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","volume":"17","author":"D DuBois","year":"1916","unstructured":"DuBois D, DuBois EF (1916) A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17:863\u2013871","journal-title":"Arch Intern Med"},{"key":"9355_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0146-6453(03)00002-2","volume":"32","author":"J Valentin","year":"2002","unstructured":"Valentin J (2002) Basic anatomical and physiological data for use in radiological protection: reference values: ICRP Publication 89. Ann ICRP 32:1\u2013277","journal-title":"Ann ICRP"},{"key":"9355_CR23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/ajcn\/39.3.427","volume":"39","author":"R Yip","year":"1984","unstructured":"Yip R, Johnson C, Dallman PR (1984) Age-related changes in laboratory values used in the diagnosis of anemia and iron deficiency. Am J Clin Nutr 39:427\u2013436","journal-title":"Am J Clin Nutr"},{"key":"9355_CR24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/(SICI)1520-6017(200001)89:1<16::AID-JPS3>3.0.CO;2-E","volume":"89","author":"P Poulin","year":"2000","unstructured":"Poulin P, Theil FP (2000) A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 89:16\u201335","journal-title":"J Pharm Sci"},{"key":"9355_CR25","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s11095-006-9210-3","volume":"24","author":"T Rodgers","year":"2007","unstructured":"Rodgers T, Rowland M (2007) Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 24:918\u2013933","journal-title":"Pharm Res"},{"key":"9355_CR26","unstructured":"Goodman LS, Gilman A (1996) Goodman & Gilman\u2019s the pharmacological basis of therapeutics\/edited by Joel G. Hardman [et al.]. McGraw-Hill, Health Professions Division, New York, London"},{"key":"9355_CR27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/cpt196892180","volume":"9","author":"TL Loo","year":"1968","unstructured":"Loo TL, Luce JK, Sullivan MP, Frei E 3rd (1968) Clinical pharmacologic observations on 6-mercaptopurine and 6-methylthiopurine ribonucleoside. Clin Pharmacol Ther 9:180\u2013194","journal-title":"Clin Pharmacol Ther"},{"key":"9355_CR28","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1651-2227.1986.tb10293.x","volume":"75","author":"P Lafolie","year":"1986","unstructured":"Lafolie P, Hayder S, Bjork O, Ahstrom L, Liliemark J, Peterson C (1986) Large interindividual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukaemia and non-Hodgkin lymphoma. Acta Paediatr Scand 75:797\u2013803","journal-title":"Acta Paediatr Scand"},{"key":"9355_CR29","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1126\/science.284.5420.1677","volume":"284","author":"GB West","year":"1999","unstructured":"West GB, Brown JH, Enquist BJ (1999) The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 284:1677\u20131679","journal-title":"Science"},{"key":"9355_CR30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0021-9258(17)43612-X","volume":"259","author":"AS Lewis","year":"1984","unstructured":"Lewis AS, Murphy L, McCalla C, Fleary M, Purcell S (1984) Inhibition of mammalian xanthine oxidase by folate compounds and amethopterin. J Biol Chem 259:12\u201315","journal-title":"J Biol Chem"},{"key":"9355_CR31","unstructured":"GetData Graph Digitizer, http:\/\/getdata-graph-digitizer.com\/ . 2013"},{"key":"9355_CR32","unstructured":"Beal S, Sheiner LB, Boeckmann A, Bauer RJ (2009) NONMEM User\u2019s Guides. (1989\u20132009). Icon Development Solutions, Ellicott City, MD, USA"},{"key":"9355_CR33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd2173","volume":"6","author":"A Rostami-Hodjegan","year":"2007","unstructured":"Rostami-Hodjegan A, Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140\u2013148","journal-title":"Nat Rev Drug Discov"},{"key":"9355_CR34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","volume":"11","author":"M Jamei","year":"2009","unstructured":"Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, Tucker G (2009) Population-based mechanistic prediction of oral drug absorption. The AAPS Journal 11:225\u2013237","journal-title":"The AAPS Journal"},{"key":"9355_CR35","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1124\/dmd.111.039248","volume":"39","author":"M Gertz","year":"2011","unstructured":"Gertz M, Houston JB, Galetin A (2011) Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab Dispos 39:1633\u20131642","journal-title":"Drug Metab Dispos"},{"key":"9355_CR36","unstructured":"Symcyp. Simcyp Limited, Sheffield, UK. 2008"},{"key":"9355_CR37","first-page":"1869","volume":"45","author":"S Zimm","year":"1985","unstructured":"Zimm S, Ettinger LJ, Holcenberg JS, Kamen BA, Vietti TJ, Belasco J, Cogliano-Shutta N, Balis F, Lavi LE, Collins JM et al (1985) Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Res 45:1869\u20131873","journal-title":"Cancer Res"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-014-9355-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-014-9355-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-014-9355-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T03:26:50Z","timestamp":1746156410000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-014-9355-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,21]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["9355"],"URL":"https:\/\/doi.org\/10.1007\/s10928-014-9355-3","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,21]]}}}